- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT02542371
Use of 99mTc Tilmanocept for Imaging Arterial Inflammation
Visão geral do estudo
Descrição detalhada
Detailed Description:
Patients with HIV have been shown to have increased atherosclerotic risk compared to age-matched controls, and this risk is thought to be related to increased systemic immune activation. Specifically, systemic immune activation may contribute to destabilizing coronary atherosclerotic plaque, leading to plaque rupture and myocardial infarction. This study is intended to measure arterial uptake of the macrophage specific marker 99mTc-Tilmanocept using single photon emission computed tomography, applied initially to a group of HIV-infected patients with known subclinical coronary atherosclerosis on CCTA. Moreover, traditional markers of CVD risk and inflammatory markers will be assessed in relation to CV imaging outcomes. Positive findings in the index HIV group with known subclinical atherosclerosis will prompt subsequent study of three comparison groups, as above.
Tipo de estudo
Inscrição (Real)
Contactos e Locais
Locais de estudo
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02114
- Massachusetts General Hospital
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Descrição
HIV infected subjects with known subclinical atherosclerosis:
Inclusion criteria:
- men and women, ages 18+, with documented HIV infection
- current use of antiretroviral therapy (ART), with no changes to regimen within last 3 months
- history of subclinical atherosclerosis on CCTA
Exclusion criteria:
- pregnancy or breastfeeding
- known active opportunistic infection requiring ongoing medical therapy (not including Hepatitis B/C)
- CD4 count < 50 cells/mm3
- history of angina, myocardial infarction, acute coronary syndrome, or coronary artery stenting or surgery
- recent and/or current treatment with prescription, systemic steroids or anti-inflammatory/immune suppressant medical therapies
- current use of statin or use of statin for > 1 month within the last 6 months
- known allergy to dextrans and/or DPTA and/or radiometals and/or iodinated contrast media
- eGFR < 60 ml/min/1.73 m2 calculated by CDK-EPI
- contraindications to beta blockers or nitroglycerin
- significant radiation exposure (>2 CT angiograms) received within the past 12 months
- BMI > 35 kg/m2 or waist circumference > 70 cm (scanner limitations)
HIV infected subjects without known subclinical atherosclerosis:
Inclusion criteria:
- men and women, ages 18+, with documented HIV infection
- current use of antiretroviral therapy (ART), with no changes to regimen within last 3 months
- history of clean aorta/ coronaries on CCTA
Exclusion criteria:
- Same as exclusion criteria for HIV infected subjects with known subclinical atherosclerosis
HIV negative subjects with known subclinical atherosclerosis:
Inclusion criteria:
- men and women, ages 18+, without documented HIV infection
- history of subclinical atherosclerosis on CCTA
Exclusion criteria:
- pregnancy or breastfeeding
- history of angina, myocardial infarction, acute coronary syndrome, or coronary artery stenting or surgery
- recent and/or current treatment with prescription, systemic steroids or anti-inflammatory/immune suppressant medical therapies
- current use of statin or use of statin for > 1 month within the last 6 months
- known allergy to dextrans and/or DPTA and/or radiometals and/or iodinated contrast media
- eGFR < 60 ml/min/1.73 m2 calculated by CDK-EPI
- contraindications to beta blockers or nitroglycerin
- significant radiation exposure (>2 CT angiograms) received within the past 12 months
- BMI > 35 kg/m2 or waist circumference > 70 cm (scanner limitations)
HIV negative subjects without known subclinical atherosclerosis:
Inclusion criteria:
- men and women, ages 18+, without documented HIV infection
- history of clean aorta/coronaries on CCTA
Exclusion criteria:
- Same as exclusion criteria for HIV negative subjects with known subclinical atherosclerosis
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Modelos de observação: Controle de caso
- Perspectivas de Tempo: Transversal
Coortes e Intervenções
Grupo / Coorte |
Intervenção / Tratamento |
|---|---|
|
HIV infected with known subclinical atherosclerosis
|
|
|
HIV infected without known subclinical atherosclerosis
|
|
|
Non-HIV infected with known subclinical atherosclerosis
|
|
|
Non-HIV infected without known subclinical atherosclerosis
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Prazo |
|---|---|
|
Aortic 99mTc-Tilmanocept uptake on SPECT/CT scanning in HIV Patients
Prazo: within 6 weeks of screening visit
|
within 6 weeks of screening visit
|
Medidas de resultados secundários
Medida de resultado |
Prazo |
|---|---|
|
Aortic plaque burden and morphology on CCTA in HIV Patients
Prazo: within 6 weeks of screening visit
|
within 6 weeks of screening visit
|
|
Traditional markers of cardiovascular disease (CVD) risk and inflammatory markers in relation to cardiovascular imaging outcomes
Prazo: within 6 weeks of screening visit
|
within 6 weeks of screening visit
|
|
Imaging assessments in the coronary vasculature in HIV patients
Prazo: within 6 weeks of screening visit
|
within 6 weeks of screening visit
|
|
Comparison of imaging assessments b/ HIV patients w/ known subclinical atherosclerosis, HIV patients w/o known subclinical atherosclerosis, non HIV patients w/ known subclinical atherosclerosis and non HIV patients w/o known subclinical atherosclerosis
Prazo: within 6 weeks of screening visit
|
within 6 weeks of screening visit
|
|
99mTc-Tilmanocept uptake on SPECT/CT in regions other than the aorta
Prazo: within 6 weeks of screening visit
|
within 6 weeks of screening visit
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Steven Grinspoon, M.D., Massachusetts General Hospital
Publicações e links úteis
Publicações Gerais
- Toribio M, Wilks MQ, Hedgire S, Lu MT, Cetlin M, Wang M, Alhallak I, Durbin CG, White KS, Wallis Z, Schnittman SR, Stanley TL, El-Fakhri G, Lee H, Autissier P, Zanni MV, Williams KC, Grinspoon SK. Increased Macrophage-Specific Arterial Infiltration Relates to Noncalcified Plaque and Systemic Immune Activation in People With Human Immunodeficiency Virus. J Infect Dis. 2022 Nov 11;226(10):1823-1833. doi: 10.1093/infdis/jiac301.
- Zanni MV, Toribio M, Wilks MQ, Lu MT, Burdo TH, Walker J, Autissier P, Foldyna B, Stone L, Martin A, Cope F, Abbruzzese B, Brady T, Hoffmann U, Williams KC, El-Fakhri G, Grinspoon SK. Application of a Novel CD206+ Macrophage-Specific Arterial Imaging Strategy in HIV-Infected Individuals. J Infect Dis. 2017 Apr 15;215(8):1264-1269. doi: 10.1093/infdis/jix095.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 2014P001832
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .